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Abstract
Background: Circulating tumor cells (CTCs) have shown prognostic relevance in many cancer types. However, the
majority of current CTC capture methods rely on positive selection techniques that require a priori knowledge
about the surface protein expression of disseminated CTCs, which are known to be a dynamic population.
Methods: We developed a microfluidic CTC capture chip that incorporated a nanoroughened glass substrate for
capturing CTCs from blood samples. Our CTC capture chip utilized the differential adhesion preference of cancer
cells to nanoroughened etched glass surfaces as compared to normal blood cells and thus did not depend on
the physical size or surface protein expression of CTCs.
Results: The microfluidic CTC capture chip was able to achieve a superior capture yield for both epithelial cell
adhesion molecule positive (EpCAM+) and EpCAM- cancer cells in blood samples. Additionally, the microfluidic
CTC chip captured CTCs undergoing transforming growth factor beta-induced epithelial-to-mesenchymal
transition (TGF-β-induced EMT) with dynamically down-regulated EpCAM expression. In a mouse model of
human breast cancer using EpCAM positive and negative cell lines, the number of CTCs captured correlated
positively with the size of the primary tumor and was independent of their EpCAM expression. Furthermore,
in a syngeneic mouse model of lung cancer using cell lines with differential metastasis capability, CTCs were
captured from all mice with detectable primary tumors independent of the cell lines’ metastatic ability.
Conclusions: The microfluidic CTC capture chip using a novel nanoroughened glass substrate is broadly applicable to
capturing heterogeneous CTC populations of clinical interest independent of their surface marker expression and
metastatic propensity. We were able to capture CTCs from a non-metastatic lung cancer model, demonstrating
the potential of the chip to collect the entirety of CTC populations including subgroups of distinct biological and
phenotypical properties. Further exploration of the biological potential of metastatic and presumably non-metastatic
CTCs captured using the microfluidic chip will yield insights into their relevant differences and their effects on tumor
progression and cancer outcomes.
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Background
While progress has been made on the prevention and
treatment of primary cancers, metastases to distant
sites remain a major clinical challenge and the main
cause of death for the majority of cancer patients [1].
Thus attention has shifted toward a better understand-
ing of the metastatic process in order to address the
mortality of patients with metastatic lesions. The
spread of cancer systemically relies upon the critical
step of the hematogenous spread of cancer cells [2].
These circulating tumor cells (CTCs) in the blood-
stream are shed from primary and metastatic lesions
and are believed to be key agents in the metastatic
process [2–4]. Therefore, capturing CTCs is not only
important to understand the determinants of the meta-
static fate of cancer cells, but also directly yields clinic-
ally relevant information as studies on CTCs have
shown a general, but not complete, negative associ-
ation between CTC counts and clinic outcomes [5–7].
The challenge being as a tumor progresses down the
metastatic cascade, cancer cells are known to express
diverse molecular phenotypes in a dynamic fashion,
which complicates the isolation of CTCs for further
study [6, 8–13]. Moreover, other cells such as fibro-
blasts and non-cancerous epithelial cells are also shed
into the circulation further complicating the identifica-
tion of the true potentially metastatic cells.
The most widely used methods for CTC capture have
relied upon tumors’ cell of origin and utilized antibodies
against tissue specific surface markers, notably epithelial
cell adhesion molecule (EpCAM), which is expressed by
epithelial cells [14–21]. However, numerous studies have
demonstrated that the EpCAM antibody-based positive
selection method is imperfect, as EpCAM expression on
cancer cells varies not only from patient to patient but
also within the same patient over time [6, 8, 9, 11, 12].
Furthermore, studies have demonstrated that epithelial-
specific markers are selectively partially or completely
down-regulated over the course of tumor dissemination
through the epithelial-to-mesenchymal transition (EMT)
[10, 13]. Other CTC capture methods utilize size-based
selection, as cancer cells are believed to be generally lar-
ger than hematopoietic and other shed cells and thus
amenable to filtration or centrifugation. However, CTCs
of various sizes, including some smaller than leukocytes,
have been reported recently [22–24]. The major chal-
lenge of CTC isolation is the extreme rarity of CTCs,
even in patients with advanced cancer. This is especially
evident when using negative selection techniques which
deplete the undesired leukocyte population using anti-
bodies against CD45, a leukocyte cell surface marker.
Thus, because of the rarity of CTCs, it is difficult for
negative selection techniques alone to achieve satisfac-
tory yields for CTC capture [25, 26].
Along the complex and dynamic progression through
the metastatic cascade there is however an important
point of convergence. The intravasation step into blood
vessels by certain cancer cells within a tumor is a
mechanically focused process by its very nature, and
only those cells capable of behaving in a precise bio-
mechanical way will successfully enter the bloodstream
as live cells [27–29]. The mechanical phenotype of a
cancer cell results from the integration of multidimen-
sional and heterogeneous factors such as cell intrinsic
genetic expression and epigenetic regulation and cancer
cell extrinsic signals from cytokines, growth factors,
and extracellular matrix proteins as well as interactions in-
volving non-cancerous immune and stromal cells [27, 30].
Given these complex inputs into the cancer cell pheno-
type, we set out to develop a method for CTC capture
that does not rely upon any one single facet of this
complex set of determinants, such as surface marker
expression, but instead relies upon an output that re-
flects the integration of the multitude of signaling path-
ways experienced by a spreading cancer cell.
To this end, we developed a method that captures
CTCs based on their differential capability to selectively
adhere to a nanoroughened glass surface as compared to
normal blood cells. In our prior work [31], we described
that a nanorough glass substrate generated by reactive-
ion etching (RIE) without any positive-selection anti-
bodies exhibits significantly improved cancer cell capture
efficiency owing to enhanced adherent interactions be-
tween the nanoscale topological features on the glass
substrate and the nanoscale cellular adhesion apparatus
[21]. In our prior work, this nanoroughened glass sub-
strate was employed to recover cancer cells spiked in
blood samples, in a fixed device setting, with capture ef-
ficiencies of over 90 % for different cancer cell lines [31].
Expanding on this proof-of-concept work, we hypothe-
sized that further improvements in CTC capture perform-
ance and blood sample throughput could be achieved by
using a confining microfluidic environment around the
nanoroughened glass substrate to promote cell-substrate
interactions for highly efficient CTC capture.
Herein we introduce our new microfluidic CTC cap-
ture platform and demonstrate its utility in recovering
cancer cells with heterogeneous molecular properties
and those obtained from two mouse models of cancer.
Our microfluidic CTC capture platform integrates two
functional components: 1) a RIE-generated nanorough-
ened glass substrate with nanoscale topological struc-
tures to enhance adherent interactions between the glass
substrate and cancer cells, and 2) an overlaid polydi-
methylsiloxane (PDMS) chip with a low profile micro-
fluidic capture chamber that promotes CTC-substrate
contact frequency. In this work we showed that the
microfluidic CTC capture chip could capture > 80 % of
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breast and lung cancer cells spiked in whole blood
samples independent of the cell lines’ EpCAM expres-
sion. The microfluidic CTC capture chip also captured
equally well A549 lung cancer cells in their epithelial- or
mesenchymal-like state before and after transforming
growth factor beta (TGF-β)-induced EMT. To further
demonstrate the clinical utility of the microfluidic CTC
capture chip, we collected whole blood from mice with
breast cancer orthotopic xenografts and demonstrated
excellent label-free CTC capture efficiency by the
microfluidic CTC capture chip. More importantly, in a
syngeneic mouse model of lung cancer utilizing cell
lines with known metastatic and non-metastatic cap-
abilities, CTCs were detected in all the mice with a de-
tectable primary tumor independent of the metastatic
propensity of the cell line implanted. This highlights
the fact that not all CTCs are capable of forming and
proliferating as metastases and our newly developed
microfluidic CTC capture device is able to recover this
less metastatically potent population as well.
Methods
Cell culture
MCF-7, MDA-MB-231, and A549 cells were acquired
from ATCC and SUM149 cells were certified via short
tandem repeat analysis (FTA barcode STR13871). 344SQ
and 393P cell lines were derived from K-ras/p53 mutant
mice as described in Gibbons et al. [32, 33]. MCF-7 cells
were maintained in high-glucose DMEM (Invitrogen);
MDA-MB-231, 344SQ, and 393P cells in RPMI-1640
(Invitrogen); SUM-149 cells in Ham’s F-12 w/L-glutam-
ine (Fisher Scientific); and A549 cells in DMEM/F12
(Invitrogen). MCF-7, MDA-MB-231, and SUM-149
media containted 0.5 μg mL−1 Fungizone, 5 μg mL−1
Gentamicin, 100 units mL−1 penicillin, and 100 μg mL−1
streptomycin (all Invitrogen). Addtionally, SUM-149 cells
were supplemented with 5 μg mL−1 Insulin and 1 μg mL−1
Hydrocortisone (both Sigma-Aldrich). A549, 344SQ, and
393P were supplemented with penicillin and streptomycin
as above [32, 33]. All media contained 10 % fetal bovine
serum (Atlanta Biological) except SUM-149 media which
had 5 %. SUM-149 cells were maintained at 37 °C with
10 % CO2 and all other cell lines at 37 °C with 5 % CO2.
Fresh 0.25 % trypsin-EDTA in phosphate buffered saline
(PBS) was used to re-suspend cells. To induce the EMT,
A549 cells were cultured with TGF-β at 5 ng mL−1 in
serum free media for 72 h. TGF-β is a potent inducer of
EMT [34–37].
Chip fabrication
The microfluidic chip includes three components: a
PDMS microfluidic chamber, an RIE-etched nanorough
glass substrate, and a polyacrylate gadget to sandwich
the chamber and substrate together. The microfluidic
chamber was generated by replica molding using a Si
mold fabricated using microfabrication. The detailed
protocol for fabrication of the microfluidic CTC capture
chip is described in the Additional file 1.
Human blood specimens
Human blood specimens from healthy donors were col-
lected in EDTA-containing vacutainers and were proc-
essed and assayed within 6 h of collection. RBC Lysis
Buffer (eBioscience) was added to whole blood at a
10:1 v/v ratio. After incubation for 10 min at room
temperature, the sample was diluted with 20–30 mL
PBS to stop the lysing reaction and then centrifuged at
300 g for 10 min. After discarding the supernatant, the
cell pellet was re-suspended in an equivalent volume of
growth medium before use in CTC capture assays.
Mouse models of cancer
Care of animals and experimental procedures were ac-
cording to the University of Michigan University Com-
mittee on Use and Care of Animals (UCUCA) approved
protocols #PRO5314 and #PRO4116. To generate breast
cancer xenografts, 1 × 106 MDA-MB-231 or SUM-149
cells were injected orthotopically into the left inguinal
mammary fat pad of each female Ncr nude mouse
(Taconic). The cells were suspended in 50 μL PBS and
50 μL Matrigel (Becton Dickinson). For the lung cancer
studies, 1 × 106 cells of two mouse lung cancer cell lines
(metastatic 344SQ and non-metastatic 393P) with differ-
ential metastatic capability [32, 33] were subcutaneously
implanted on either side of the dorsal flank in C57BL/6
mice (Taconic). Tumor growth was monitored weekly by
caliper measurement with ellipsoid volumes calculated
using ½ x length × width × height. Before euthanizing the
mice, blood samples (0.3–0.8 mL) were collected via car-
diac puncture under anesthesia to quantify CTCs.
CTC capture from in vitro spiked blood samples
Prior to CTC capture assays, cancer cells were first la-
beled with CellTracker Green (Invitrogen) before mixed
with Δ9-DiI-stained (Invitrogen) leukocytes in lysed
blood. The total cancer cell number in the blood sam-
ple was first quantified using a hemocytometer before
the spiked sample was diluted using lysed whole blood
to achieve the desired final CTC concentration. For the
capture of pre- and post-EMT A549 cells in admixture,
pre- and post-EMT A549 cells were first labeled with
CellTracker Green (Invitrogen) and CellTracker Blue
(Invitrogen), respectively, before mixed in cell culture
medium.
The CTC capture chip was assembled and connected
to a custom-built pressure control setup. The PDMS
microfluidic chamber was washed with PBS for 5 min
before 1.0 mL of spiked blood sample was loaded at a
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flow rate of 200 μL min−1 and incubated for 30 min -
1 h at 37 °C with 5 % CO2. After the CTCs adhered, the
chamber was washed with PBS then loaded with 4 %
paraformaldehyde (PFA; Electron Microscopy Sciences)
in PBS for 20 min to fix captured CTCs. The nanorough
glass substrate was then detached from the PDMS
chamber and rinsed with PBS to remove floating cells.
Adherent cells immobilized on the nanorough glass sub-
strate were then imaged directly using a fluorescence
microscope (Nikon Eclipse Ti-S, Nikon) equipped with
an electron multiplying charge-coupled device (EMCCD)
camera (Photometrics). To quantify CTC capture yield,
the entire glass surface area was scanned on a motorized
stage (ProScan III, Prior Scientific). Image processing
software ImageJ (National Institutes of Health) was used
to determine the number of CTCs.
CTC capture from in vivo mouse models
Capture of CTCs from mouse blood samples was per-
formed using a procedure similar to the one employed
for spiked blood samples. To visualize and quantify
CTCs captured on the nanorough glass substrate, immu-
nostaining was performed after the glass substrate was
detached from the microfluidic chamber. After the PBS
rinse as above, adherent cells were permeabilized with
0.25 % Triton X-100 (Roche Applied Science) in PBS for
10 min. Fixed cells were incubated with 10 % goat serum
(Invitrogen) for 1 h before another 1 h incubation with
primary antibodies to cytokeratin (FITC; BD Biosci-
ences) and mouse CD45 (PE) and DAPI to identify can-
cer cells, leukocytes, and cell nuclei, respectively. CTCs
were identified by: positive staining of anti-cytokeratin
and DAPI; negative staining of anti-CD45; and appropri-
ate morphometric characteristics including cell size,
shape, and nuclear size. The researcher counting CTCs
was blinded to the mouse group and tumor characteristics.
Statistical analysis
Student’s two-sample, unpaired t-tests were calculated
using GraphPad Prism software with P-values < 0.05
considered statistically significant.
Results
Capture of cancer cells independent of surface protein
expression
We have recently developed a simple yet precisely con-
trolled method to generate random nanoroughness on
glass surfaces using reactive ion etching (RIE) [38]. RIE-
based nanoscale roughening of glass surfaces is consist-
ent with a process of ion-enhanced chemical reaction
and physical sputtering [39]. In our previous work, we
have shown that bare glass surfaces treated with RIE for
different periods of time can acquire different levels of
roughness (as characterized by the root-mean-square
roughness Rq; Rq = 1–150 nm) with a nanoscale reso-
lution (Additional file 1: Figure S1) [38]. To validate the
efficiency of RIE-generated nanorough glass surfaces
(Fig. 1a) for the capture of cancer cells with different
surface protein expression, three breast cancer cell lines,
MCF-7 (EpCAM-positive, or EpCAM+), SUM-149
(EpCAM+), and MDA-MB-231 (EpCAM-negative, or
EpCAM-) [40–42] spiked in minute amounts in culture
medium (1,000 cells in 1 mL medium) as single cells
were injected into the microfluidic CTC capture chip
with either a smooth glass surface (Rq = 1 nm) or a
nanoroughened glass surface (Rq = 150 nm) for 30 min.
Quantitative analysis revealed that the capture yield of
cancer cells, defined as the ratio of the number of cancer
cells captured on the glass surface to the total number
Fig. 1 Nanotopography-based microfluidic chip for CTC capture.
a Photo of the microfluidic CTC capture chip (left) and SEM images
(right) showing the nanorough glass surface (top right, Rq = 150 nm)
and a cancer cell adhered to the surface (bottom right). b Bar
graph showing 30 min capture yield for breast cancer cells (MCF-7,
MBA-MB-231, and SUM-149) and lung cancer cells (A549) using the
capture chip with smooth (Rq = 1 nm) and nanorough (Rq = 150 nm)
glass surfaces as indicated. For each cell type, 1,000 cells were spiked in
1 mL lysed human blood. EpCAM expression of each cell line is
denoted below the graph. Error bars, s.e.m. (n = 4). **, p < 0.01
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of cells initially seeded, was 85.7, 80.9, and 86.5 % for
MCF-7, SUM-149, and MDA-MB-231, respectively, for
the nanorough glass surface with Rq = 150 nm (Fig. 1b).
Additional passes of the spiked blood samples over the
device did not increase yields further (data not shown).
In distinct contrast, experiments using the smooth glass
surface with Rq = 1 nm showed drastically lower capture
yields for MCF-7, SUM-149, or MDA-MB-231 cells
(6.7 % for MCF-7, 8.0 % for SUM-149, and 8.7 % for
MDA-MB-231) (Fig. 1b). We further performed cell cap-
ture assays using the EpCAM+ A549 lung cancer cell
line [43] and observed a similarly significant enhance-
ment of cancer cell capture yield by the nanoroughened
glass surface (Fig. 1b). Leukocyte capture yields were
similar to our previously reported results [31]. Together,
our results in Fig. 1 suggest a very strong propensity for
cancer cells to adhere to RIE-generated nanorough glass
surfaces regardless of the cells’ EpCAM expression sta-
tus, and further support a superior efficiency of the
label-free nanoroughened glass substrate for capturing
CTCs.
Capture of cancer cells before and after TGF-β-induced
epithelial-mesenchymal transition
Through the metastatic cascade, tumor cells are posited
to undergo an EMT, which alters adhesive surface pro-
tein expression along with many other aspects of cellular
behaviors [44, 45]. During this EMT, in addition to ac-
quiring a migratory and invasive phenotype, tumor cells
express mesenchymal proteins and concomitantly lose
epithelial markers including the expression of EpCAM
[46]. To demonstrate specifically that the capture of can-
cer cells by the RIE-generated nanorough glass substrate
was independent of a cancer cell’s epithelial or mesen-
chymal state, we used the A549 cell culture model of
TGF-β-induced EMT and spiked known quantities of
pre- and post-EMT A549 cells (n = 40–10,000) into
500 μL lysed human blood (Fig. 2a). After culture with
Fig. 2 Capture of pre- and post-EMT lung cancer cells using the nanotopography-based microfluidic CTC capture chip. a Representative staining
images showing pre- (top) and post-EMT (bottom) A549 cells captured on nanorough glass surfaces (Rq = 150 nm) 1 h after cell seeding. 10,000
pre- and post-EMT A549 cells labeled with CellTracker Green were spiked in 500 μL lysed blood that was pre-stained with DiI to label peripheral
blood mononuclear cells (PBMCs). b & c Regression analysis of 1 h capture efficiency for pre- and post-EMT A549 cells (n = 40–900 spiked in
500 μL lysed blood) using the microfluidic CTC capture chip. The number of A549 cells captured (b) and the capture yield (c) is plotted as a
function of the total number of A549 cells spiked in blood samples. d Ratio of pre- and post-EMT A549 cells captured 1 h after cell seeding as
a function of their ratio when spiked in blood samples. 1,000 post-EMT A549 cells were mixed with 500–4,000 pre-EMT cells in 500 μL lysed
blood to achieve ratios from 2 : 1 to 1 : 4. Solid lines in b & d represent linear fitting. Error bars, s.e.m. (n > 4)
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TGF-β for 72 h, A549 cells express significantly reduced
levels of EpCAM mRNA (Additional file 1: Figure S2)
[47]. Yet despite these lung cancer cells’ dynamic
EpCAM expression, high capture yields were achieved
when seeding the cells for 1 h in the microfluidic CTC
capture chip with a nanoroughened glass surface (Rq =
150 nm) for both pre- and post-EMT A549 lung cancer
cells, even at extremely low cancer cell concentrations
(80 cells mL−1) (Fig. 2b & c). Strong linear correlations
between the number of cancer cells captured vs. the
number of cancer cells initially loaded (n = 40–900) were
observed for both pre- and post-EMT A549 cells
(Fig. 2b). Averaged across all cell concentrations assayed
(80–20,000 cells mL−1), capture yields were 89.4 % ±
5.3 % for post-EMT A549 cells and 89.2 % ± 2.2 % for
pre-EMT A549 cells (Fig. 2c, Additional file 1: Fig. S2).
We further examined the effect of admixtures of pre-
and post-EMT A549 cells on capture efficiency by vary-
ing the ratio of pre- and post-EMT A549 cells spiked in
the same blood sample. Here 1,000 post-EMT A549 cells
were mixed with 500–4,000 pre-EMT cells in 500 μL
lysed blood to achieve a cell ratio from 2 : 1 to 1 : 4
(Fig. 2d). Cell capture assays using the microfluidic CTC
capture chip for 1 h revealed that capture yield was not
significantly affected by the relative proportions of pre-
or post-EMT A549 cells with differing EpCAM expres-
sion and remained constant over the entire range of cell
ratios of pre- and post-EMT A549 cells (Fig. 2d). To-
gether, our results in Fig. 2 support that the RIE-
generated nanorough glass surfaces can achieve efficient
capture of CTCs independently of the cancer cell’s epi-
thelial or mesenchymal state or EpCAM expression,
demonstrating the applicability of the microfluidic CTC
capture device for the capture and enumeration of rare
tumor cells from heterogeneous cell samples and
throughout a tumor’s metastatic progression, even in the
setting of a dynamic EMT process.
Capture of CTCs from a human breast cancer orthotopic
xenograft mouse model
We next assayed the microfluidic CTC capture chip with
a nanoroughened glass surface (Rq = 150 nm) using an
orthotopic xenograft mouse model of breast cancer. To
generate tumor xenografts (Fig. 3a), 1 × 106 MDA-MB-
231 (EpCAM-) or SUM-149 (EpCAM+) breast cancer
cells were injected into the left inguinal mammary fat
pad of female Ncr nude mice [48]. When mice were eu-
thanized to assess for tumor burden between 3 - 7 weeks
of xenograft time, nearly the entire mouse blood volume
(300–800 μL) was collected by cardiac puncture of the
left ventricle from each mouse before assayed using the
microfluidic CTC capture chip. CTCs, as defined by
cytokeratin+, CD45-, DAPI+ staining (Fig. 3b), were suc-
cessfully captured from 11 out of 12 mice bearing tumor
xenografts of MDA-MB-231 cells and from all 5 mice
with tumor xenografts of SUM-149 cells (Table 1). Data
pooled from both EpCAM+ and EpCAM- breast cancer
mouse models showed that the number of CTCs cap-
tured by the microfluidic CTC capture chip ranged from
13 to 4,664 cells per 100 μL of blood and increased dras-
tically over the 9-week period during tumor progression,
correlating positively with an increase in tumor weight
(Fig. 3c-e).
Capture of CTCs from metastatic and non-metastatic
syngeneic mouse models of lung cancer
We next sought to assay the microfluidic CTC capture
chip using a syngeneic mouse model of lung cancer.
Two well-defined mouse lung cancer cell lines (344SQ
and 393P) with different metastatic capabilities were
subcutaneously implanted in a syngeneic host. Even
though 344SQ and 393P lung cancer cells have distinct
metastatic potential, both cell lines are derived from the
same transgenic mouse model of lung cancer (p53 null,
mutant Kras) [32, 33]. The 344SQ lung cancer cells form
metastatic lesions from spontaneous and experimental
metastatic assays (subcutaneous implantation and tail
vein injection), whereas the 393P cell line does not
metastasize by either assay [32]. However, both cell lines
are capable of undergoing EMT in response to TGF-β
with different kinetics and lose expression of epithelial
markers [32, 33].
After 6 weeks of subcutaneous tumor growth, mice
were sacrificed and whole blood was collected via car-
diac puncture before being processed with the micro-
fluidic CTC capture chip with a nanoroughened glass
surface (Rq = 150 nm) (Additional file 1: Figure S3).
Simultaneously, primary tumor volumes were measured
and lungs were examined grossly for metastasis (Fig. 4a).
The 344SQ primary tumors grew significantly larger
and shed more CTCs than metastasis-incompetent
393P tumors (Fig. 4c-f ). Using the microfluidic CTC
capture chip, CTCs were detected in all five mice im-
planted with the metastatic 344SQ cell line (Fig. 4d,
Table 2). Similar to results from the breast cancer xeno-
graft model, the number of CTCs detected using the
microfluidic CTC capture chip showed a positive cor-
relation with primary tumor size (Fig. 4g). As expected,
neither of the two mice implanted with the metastasis-
incompetent 393P lung cancer cell line that formed
palpable primary tumors (mice #6 and 7) had detect-
able metastatic lesions on their lungs (Fig. 4, Table 2).
Surprisingly, however, we detected the presence of
CTCs in all the mice, including those mice with metas-
tasis incompetent 393P implants, with palpable primary
tumors (Fig. 4d). This observation clearly demonstrates
that the presence of CTCs alone may not be indicative
of the presence of metastatic disease.
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Discussion
In this work, we have successfully developed a microflui-
dic CTC capture chip utilizing an RIE-generated nanor-
ough glass surface as the substrate for efficient capture
of CTCs regardless of cell size or surface protein expres-
sion. The microfluidic flow chamber incorporated on
top of the nanorough glass surface promotes greater ad-
hesive interactions of cancer cells with the nanorough
glass substrate, thereby providing an effective strategy to
achieve superior CTC capture efficiency. Other efforts
that have been undertaken to isolate CTCs have primar-
ily depended on either physical size differences between
cancer cells and hematocytes or on the surface protein
expression of either cancer cells or leukocytes [14–24,
49, 50]. In contrast, our CTC capture strategy leverages
the differential adhesion preference to the RIE-generated
nanorough glass surfaces between cancer cells and nor-
mal blood cells [31]. Mechanical properties of cancer
cells represent a point of convergence in the metastatic
cascade whereby only those cells within a tumor behav-
ing in a precise biomechanical manner will successfully
intravasate into the bloodstream. Since the mechanical
phenotype of a cancer cell is the culmination of an array
of heterogeneous factors both cell intrinsic and cell ex-
trinsic [27, 30], we posit that using a CTC capture sys-
tem that is mechanically focused and adhesion-based
will have greater success in detecting CTCs with differ-
ent molecular signatures. This fact was supported by this
present study as our adhesion-based microfluidic CTC
capture chip was capable of capturing heterogeneous
Fig. 3 CTCs captured using the microfluidic CTC capture chip from mice with breast cancer orthotopic xenografts. a Photos of MDA-MB-231
xenografts, 1 cm scale bar. The arrow indicates the small tumor at 3 weeks. b Representative staining images showing CTCs captured on
nanorough glass surfaces from mice with MDA-MB-231 tumor xenografts. Cells were co-stained for nuclei (DAPI; blue), cytokeratin (green),
and CD45 (red). c-e Temporal changes in CTC number and tumor weight during tumor progression. Tumor weight (c) from mice with MDA-MB-231
and SUM-149 tumor xenografts as a function of xenograft time. Scatter plot (d) of CTC number per 100 μL blood vs. tumor weight. Bar plot
(e) showing number of CTCs captured by the microfluidic CTC chip as a function of xenograft time. For each CTC capture assay, 300–800 μL
blood samples were obtained via cardiac puncture. Error bars, s.e.m
Chen et al. BMC Cancer  (2016) 16:614 Page 7 of 12
Fig. 4 Capture of CTCs from metastatic and non-metastatic syngeneic mouse models of lung cancer. a Photos of lung metastases from
344SQ (top) and 393P (bottom) implants. Mouse 344SQ lung cancer cells are highly metastatic, while mouse 393P lung cancer cells are
metastasis-incompetent. b Representative staining images showing CTCs captured on nanorough glass surfaces from mice implanted with
344SQ cells. Cells were co-stained for nuclei (DAPI; blue), cytokeratin (green), and CD45 (red). c-g Analysis of CTC number and tumor volume for mice
with 344SQ and 393P tumor allografts. Bar plots show tumor volume (c) and CTC number per 100 μL blood (d) for individual mice. Bar plots showing
average tumor volume (e) and average CTC number per 100 μL blood (f) of all mice. Scatter plot (g) of CTC number per 100 μL blood vs.
tumor volume for mice with 344SQ and 393P tumor allografts. Mice were subcutaneously implanted with tumor allografts of 344SQ and 393P
lung cancer cells. For each CTC capture assay, 350–600 μL blood samples were obtained via cardiac puncture. Error bars, s.e.m. *, p < 0.05
Table 1 Capture of CTCs from mice with orthotopic breast cancer xenografts
Group Sample Xenograft time End tumor weight (g) Collected blood volume (μL) Captured CTCs (CTCs/100 μL)
MDA-MB-231 #1 3 weeks 0.05 800 16
#2 0.08 800 498
#3 5 weeks 0.20 800 29
#4 0.17 800 13
#5 0.30 800 772
#6 0.10 800 468
#7 0.12 500 478
#8 7 weeks 0.60 800 1348
#9 0.30 800 259
#10 0.32 800 261
#11 9 weeks 0.20 800 0
#12 0.60 800 4664
SUM-149 #13 5 weeks 0.22 300 675
#14 0.20 800 306
#15 0.24 700 1366
#16 7 weeks 0.30 500 579
#17 0.40 700 4408
MDA-MB-231 or SUM-149 xenografts of 1 × 106 cells were grown before blood collection and enumeration of CTCs
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CTC populations independent of their EpCAM expression
status or phenotypic state along the epithelial-mesenchymal
continuum. Specifically, with the microfluidic CTC
capture device, we were able to achieve capture yields
of > 80 % for both EpCAM+ (MCF-7, SUM-149, A549)
and EpCAM- (MDA-MB-231) cancer cell lines spiked
in whole blood samples. While our present system re-
lied upon the fixation and staining of cells to verify
CTC capture, the process could easily be altered to
forgo this step instead detach viable cells for down-
stream single-cell sequencing studies and analysis.
Furthermore, the microfluidic CTC capture device
attained high capture yields for both pre- and post-
EMT lung cancer cells – and with equal affinity – in
an in vitro model of induced EMT. Unbiased efficient
capture of heterogeneous populations of CTCs regard-
less their EpCAM expression status is important, as
EpCAM expression in tumor cells varies between pa-
tient to patient and within a patient over time as it is
rapidly down-regulated during EMT. Similarly, many
other surface markers on cancer cells are dynamically
expressed over the course of tumor dissemination and
the metastatic cascade [9–11, 51, 52]. Therefore, the
precise surface marker expression of CTCs is a mov-
ing target during tumor progression, requiring capture
methods targeting the whole CTC population to be in-
dependent of CTCs’ surface marker expression.
Although there are several other microfluidic platforms
capable of achieving high CTC capture efficiency, many of
them depend on the use of positive selection agents (i.e.
anti-EpCAM antibody or aptamer) [6, 8, 53, 54]. These
methods inherently require a priori assumption about
the surface protein expression of CTCs that have been
proven to be a dynamic and inconsistent population
[6, 8]. Some tumor cells may shed from the primary
tumor and enter the bloodstream after undergoing the
EMT process and losing their epithelial properties [45, 55].
It has been proposed that the EMT process may addition-
ally cause a series of other CTC feature changes apart from
the loss of epithelial properties, such as enhanced inva-
siveness and elevated resistance to apoptosis [56]. In
agreement with this, a recent study has revealed dy-
namic changes of epithelial and mesenchymal composi-
tions of CTCs with disease progression among patients
with breast cancer [9]. Together, it is clear that some
CTCs may experience phenotypic changes during
tumor evolution and that the expression of EpCAM
may be transient, so EpCAM expression based methods
may potentially miss a substantial subset of CTCs [57, 58].
Thus, any positive marker-based selection method can
bias captured CTCs toward a population that is not
representative of the CTCs in a patient [8, 59]. The lim-
ited number of CTCs detected in patients even in late
stages of metastases may well be a result of the use of
CTC detection methods that heavily rely on EpCAM
expression by CTCs [60–62]. New methods, like the
microfluidic CTC capture chip using the label-free
nanoroughened glass substrate, are critically needed to
capture the entirety of heterogeneous CTC populations.
In this work we have shown that by focusing on a bio-
mechanical property dependent on a multitude of cellular
signals, we can capture CTCs in different morphologic
states and irrespective of EpCAM expression, thus our
adhesion-based microfluidic CTC capture is marker and
molecular independent.
To advance the clinical relevance of our microfluidic
CTC capture chip further, we studied two in vivo models
of breast and lung cancer. In orthotopic xenografts of
EpCAM+ and EpCAM- breast cancer cell lines, clear
correlations between tumor size and CTC number were
observed for both MDA-MB-231 and SUM-149 xeno-
grafts, supporting the independence of our CTC capture
methodology from cell surface marker expression. Our
adhesion-based method for capturing heterogeneous
CTC populations was further demonstrated by the use
of a syngeneic lung cancer mouse model with differential
metastatic capabilities. In this model, a positive correl-
ation between primary tumor size and CTC number was
Table 2 Capture of CTCs from metastatic and non-metastatic syngeneic mouse models of lung cancer
Group Sample End tumor volume (mm3) Collected blood volume (μL) Captured CTCs (CTCs/100 μL)
Metastasis-Prone (344SQ) #1 179 500 84
#2 144 500 28
#3 1470 350 336
#4 503.5 500 84
#5 988 500 1148
Metastasis-Incompetent (393P) #6 15.8 400 28
#7 40 350 112
#8 No tumor 500 0
#9 No tumor 600 0
The metastasis-prone 344SQ or metastasis-incompetent 393P lung cancer cell lines were subcutaneously implanted into mice that were sacrificed 6 weeks after
implantation with blood collected for circulating tumor cell quantification
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observed. Interestingly, CTCs were also detected by our
microfluidic CTC capture chip in two mice implanted
with the non-metastatic 393P cell line. These mice did
not grow overt lung metastases as did all the mice in the
metastatic 344SQ cell line cohort. Thus, a population of
CTCs incapable of forming metastases was detected by
the microfluidic CTC capture chip, supporting that cel-
lular signals and biological processes that allow for in-
dividual cell invasion and intravasation are not identical
to those governing the seeding of fruitful metastases. It
is important to understand the differences in the nature
of these CTCs to determine their true significance in
patient prognosis and in the clinical management of
cancer, and our microfluidic CTC capture chip allows
for both populations’ study with its unbiased capture
method based on the selective adhesion of cancer cells.
Conclusions
In summary, we have developed a promising strategy
for broad-based CTC capture by exploiting the prefer-
ence of cancer cells to adhere to RIE-generated, nanor-
oughened glass surfaces that is independent of CTCs’
marker expression or epithelial-mesenchymal state,
both of which change throughout the development of a
tumor and metastases. We show that our microfluidic
CTC capture method is broadly applicable to capturing
heterogeneous CTC populations in vitro and in two
animal models of cancer, demonstrating its potential to
collect highly diverse CTC subgroups. Future exploration
of the molecular and functional differences in different
subpopulations of CTCs captured with our nanorough-
ened methodology will yield insights into their differential
effects on tumor progression and outcomes.
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